Neonc Technologies Inc. (NTHI)
NASDAQ: NTHI
· Real-Time Price · USD
5.12
-0.08 (-1.54%)
At close: Aug 20, 2025, 10:03 AM
Company Description
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases.
Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing.
The company was incorporated in 2023 and is based in Los Angeles, California.
Neonc Technologies Inc.
| Country | United States |
| IPO Date | Mar 26, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Thomas C. Chen |
Contact Details
Address: 8335 Sunset Boulevard Calabasas, California United States | |
| Website | https://www.neonctech.com |
Stock Details
| Ticker Symbol | NTHI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001979414 |
| CUSIP Number | n/a |
| ISIN Number | US64051A1016 |
| Employer ID | 92-1954864 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Thomas C. Chen M.D., Ph.D. | Founder, Chief Executive Officer, Chief Scientific Officer & Director |
| Keithly A. Garnett | Chief Financial Officer & Director |
| Patrick Walters CPA | Chief Operating Officer |
| Amir Farrokh Heshmatpour | President, Executive Chairman & Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 18, 2025 | 10-Q | Quarterly Report |
| Aug 18, 2025 | 8-K | Current Report |
| Aug 14, 2025 | NT 10-Q | Filing |
| Aug 13, 2025 | 8-K | Current Report |
| Aug 01, 2025 | 8-K | Current Report |
| Jul 30, 2025 | 8-K | Current Report |
| Jul 25, 2025 | 8-K | Current Report |
| Jul 22, 2025 | 8-K | Current Report |
| Jul 10, 2025 | 8-K | Current Report |
| Jun 16, 2025 | 424B5 | Filing |